3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
HER2-negative Breast Cancer
1
Gastric Adenocarcinoma
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Paclitaxel
134
Carboplatin
129
Bevacizumab
86
Gemcitabine
45
pembrolizumab
37
olaparib
33
Cisplatin
30
liposomal doxorubicin
29
Docetaxel
29
Cyclophosphamide
29
Topotecan
28
niraparib
27
Taxes
20
Etoposide
18
Filgrastim
16
Doxorubicin
16
Immunoglobulin G
15
Disulfides
15
apatinib
12
Letrozole
12
Albumin-Bound Paclitaxel
12
Drug Therapy
11
fluzoparib
10
fludarabine
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Biopsy
10
durvalumab
9
Nivolumab
9
pazopanib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ovarian Neoplasms
×
taxane
×
Clear all
NCT01669226
2016-12-19
AICE
Shanghai Gynecologic Oncology Group
Phase 2
Completed
215 enrolled